Denali says Zafinofusp Alfa Sanfilippo study completed primary endpoint treatment period; data due Q1 2027

Denali Therapeutics says the Phase 1/2 study of Zafinofusp Alfa in Sanfilippo syndrome has completed the primary endpoint treatment period, with data expected in Q1 2027.

Detected & updated continuously · Source: Nebula